Ovid Therapeutics INC 10-K annual reports

Ovid Therapeutics Inc. reported a reduced net loss for 2025, driven by increased revenue and successful capital raises, as it advances its pipeline of brain disorder treatments.

Ovid Therapeutics files an amendment to its annual report to include information required by Items 10 through 14 of Part III, related to directors, executive officers, compensation, and corporate governance.

Ovid Therapeutics' 2024 10-K filing details the company's focus on developing small molecule medicines for brain conditions, pipeline advancements, and financial strategy for long-term stockholder value.

Ovid Therapeutics' 10-K filing details its capital structure, pipeline progress, and strategic focus on developing novel treatments for epilepsies and neurological disorders with seizure symptoms.